Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

25.800
+0.4001.57%
Volume:6.72M
Turnover:173.89M
Market Cap:22.50B
PE:27.99
High:26.800
Open:25.300
Low:24.750
Close:25.400
Loading ...

HUTCHMED (China) Ltd - Announces Orpathys to Remain on China's Nrdl in 2025

THOMSON REUTERS
·
28 Nov 2024

HUTCHMED Announces Continued Inclusion of Orpathys® (Savolitinib) in the National Reimbursement Drug List in China at Current Terms

THOMSON REUTERS
·
28 Nov 2024

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

GlobeNewswire
·
28 Nov 2024

Kotra Industries Bhd Malaysia 1st-Quarter 2024 Earnings Summary Table

Dow Jones
·
27 Nov 2024

BRIEF-HUTCHMED Announces Launch By Takeda Of Fruzaqla® (Fruquintinib) In Japan

Reuters
·
22 Nov 2024

HUTCHMED Announces Launch by Takeda of Fruzaqla® (Fruquintinib) in Japan

THOMSON REUTERS
·
22 Nov 2024

Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan

MT Newswires Live
·
22 Nov 2024

HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%

MT Newswires Live
·
22 Nov 2024

Press Release: HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Dow Jones
·
20 Nov 2024

- HUTCHMED China Ltd - Clinical Data to Be Presented at Ash and Esmo Asia

THOMSON REUTERS
·
06 Nov 2024

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

GlobeNewswire
·
06 Nov 2024

HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales

MT Newswires Live
·
31 Oct 2024

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in Fruzaqla® (Fruquintinib) Sales by Takeda

THOMSON REUTERS
·
31 Oct 2024

Press Release: HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA(R) (fruquintinib) Sales by Takeda

Dow Jones
·
31 Oct 2024

Hutchmed Says Combination Lung Cancer Therapy Shows Efficacy in Phase 2 Study

MT Newswires Live
·
16 Oct 2024

Hutchmed's Phase 2 Trial for Lung Cancer Drug Combination Shows 'Favorable' Response

MT Newswires Live
·
16 Oct 2024